Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company, Wednesday priced public offering of 6.64 million shares at $18 per share.
The company also priced pre-funded warrants to purchase up to 3.09 million common shares at $17.99 per pre-funded warrant. The pre-funded warrants will be immediately exercisable with an exercise price of $0.01 per share.
Xencor intends to use the net proceeds from the offering of about $175 million for general corporate purposes, including research and development, capital expenditures, working capital and general and administrative expenses.
Leerink Partners, Raymond James and RBC Capital Markets are acting as joint book-running managers for the offering, which is expected to close by September 12.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.